PROs In Diabetes: FDA Panel Wanted Data Proving Insulin Icodec’s ‘Theoretical’ Benefits In Type 1

 
• By Sue Sutter
Once a week
Novo failed to prove the benefits of once-weekly basal insulin dosing. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers